Background Pegylated interferon (peginterferon) alfa 2a or 2b plus ribavirin regimens were
the standard of care in patients with hepatitis C virus (HCV) infection, but the sustained …

Asia is endemic for hepatitis C virus (HCV) infection, which is the leading cause of cirrhosis,
hepatic decompensation, hepatocellular carcinoma, and liver transplantation worldwide …

Hepatitis C virus (HCV) remains one of the leading causes of morbidity and mortality
worldwide. Combined therapy with pegylated interferon (PEG‐IFN) and ribavirin is the …

Background Pegylated interferon (peginterferon) plus ribavirin is the recommended
treatment for patients with chronic hepatitis C, but systematic assessment of the effect of this …

Background A combination of weekly pegylated interferon (peginterferon) alpha and daily
ribavirin still represents standard treatment of chronic hepatitis C infection in the majority of …

Background Randomized clinical trials (RCTs) of interventions for the hepatitis C virus have
historically used sustained virological response (SVR) at 24 weeks after treatment (SVR24) …

Background Optimal therapy for children with chronic hepatitis C is unclear. Two treatment
regimens are currently licensed in children. Objectives To assess the clinical effectiveness …

Purpose We aimed to compare the rates of sustained virologic response (SVR) achieved
with peginterferon (PEG-IFN) alfa-2a and alfa-2b in combination with ribavinin (RBV) for …

В монографии на основе анализа данных современной литературы и результатов
собственной работы обсуждаются различные аспекты эпидемиологии, патогенеза …

Elucidation of the natural history of chronic hepatitis C (CHC) and the identification of risk
factors for its progression to advanced liver disease have allowed many physicians to …